Use of glucose‐lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose‐lowering drug groups. Issue 12 (9th September 2019)

• Record Type: Journal Article
• Authors: Csatordai, M.; Benkő, R.; Matuz, M.; Bor, A.; Lengyel, C.; Doró, P.
• Is Part Of: Diabetic medicine. Volume 36:Issue 12(2019)
• Page Start: 1612
• Page End: 1620
• Publication Date: 2019-09-09
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.14117
• Languages: English
• ISSNs: 0742-3071

Abstract

Abstract: Aims: To analyse glucose‐lowering drug utilization, focusing on the novel glucose‐lowering drug groups dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors, and the financial burden they entail. Methods: Crude reimbursed national drug utilization and expenditure data for the entire population of Hungary were obtained from the National Health Insurance Fund for the study period: 2008 to 2017. Data were analysed using the WHO's Anatomical Therapeutic Chemical Classification/defined daily dose system and were expressed in defined daily dose per 1000 inhabitants per day. Results: Total glucose‐lowering drug consumption in Hungary showed an 18% increase over the study period, reaching 74.7 defined daily doses per 1000 inhabitants per day, while novel glucose‐lowering drug use increased to 11.7 defined daily doses per 1000 inhabitants per day (16% of total glucose‐lowering drug use) by 2017. Dipeptidyl‐peptidase 4 inhibitor consumption grew to 7.4 defined daily doses per 1000 inhabitants per day by 2017. The most widely used dipeptidyl‐peptidase 4 inhibitor was sitagliptin. Glucagon‐like peptide‐1 receptor agonists were used the least, but by 2017 rose to 1.5 defined daily doses per 1000 inhabitants per day, led by liraglutide. Sodium‐glucose co‐transporter‐2 inhibitors appeared in the utilization data in 2014 and their consumption, mainly empagliflozin, reached 2.8 defined daily doses per 1000 inhabitants per day by 2017. The total expenditure on glucose‐lowering drugs increased 94% between 2008 and 2017, and the total cost of novel glucose‐lowering drug utilization comprised 44% of the total glucose‐lowering drug expenditure in 2017. Conclusions: Both the use of and the financial burden posed by novel glucose‐lowering drugs in Hungary increased steadily between 2008 and 2017. This increase is expected to continue. What's new?: The use of glucose‐lowering drugs has increased continuously over the past decade. Since 2008 the use of these medications in Hungary [expressed in defined daily dose per 1000 inhabitants per day (DDD/TID)] has grown by 18%. The use of novel glucose‐lowering drug groups (dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors) has steadily increased, reaching 16% of the total glucose‐lowering drug consumption (expressed in DDD/TID) in 2017. The total expenditure on glucose‐lowering medicines has increased by 94% since 2008. Novel glucose‐lowering drug use places a high financial burden both on people with diabetes and the healthcare system.